DNTH

Dianthus Therapeutics, Inc.$76.08-4.08 (-5.10%)

Prev Close$80.00·MCap$2.84B·P/E—·Vol378.3K·Yield—

▲

Buys (12M)

$0.00

▼

Sells (12M)

$25.32M

◆

Net Activity

Net Seller

$25.32M

●

Active Insiders

last 12 mo

Over the past 12 months, insider activity at Dianthus Therapeutics, Inc. (DNTH) has been exclusively selling, with 0 insider purchases totaling $0.00 and 6 insider sales totaling $25.32M. The most recent insider transaction was by CARR EDWARD (officer: CHIEF ACCOUNTING OFFICER), who sold $3.56M worth of shares on Mar 13, 2026. Dianthus Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.84B.

DNTH Insider Trading Activity

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Mar 13, 2026	CARR EDWARD	officer: CHIEF ACCOUNTING OFFICER	Sell	43,682	$81.49	$3.56M	27,830
Mar 13, 2026	Garcia Marino	director, officer: CEO AND PRESIDENT	Sell	122,918	$81.49	$10.02M	79,413
Mar 13, 2026	Randhawa Simrat	officer: EVP, Head of R&D	Sell	33,830	$81.48	$2.76M	0
Dec 4, 2025	Savitz Ryan	CFO & CBO	Sell	20,000	$45.18	$903.6K	0
Nov 13, 2025	Randhawa Simrat	EVP, Head of R&D	Sell	196,538	$37.55	$7.38M	0
Sep 9, 2025	Savitz Ryan	CFO & CBO	Sell	20,000	$35.00	$700.0K	0
Oct 3, 2023	Fairmount Funds Management LLC	Director	Buy	24,670	$13.63	$336.3K	1,928,503
Sep 28, 2023	Fairmount Funds Management LLC	Director	Buy	30,000	$13.15	$394.5K	1,903,833
Sep 25, 2023	Randhawa Simrat	Chief Medical Officer	Buy	4,000	$13.20	$52.8K	4,000
Sep 21, 2023	Fairmount Funds Management LLC	Director	Buy	30,000	$13.20	$396.0K	1,873,833
Sep 13, 2023	Fairmount Funds Management LLC		Buy	24,254	$11.20	$271.7K	1,843,833
Feb 9, 2023	Third Rock Ventures IV, L.P.	10% Owner	Sell	3,700,000	$0.83	$3.06M	4,558,204
Sep 20, 2021	Beetham Thomas W.	See Remarks	Sell	6,103	$6.73	$41.1K	13,897
Sep 20, 2021	Deardorf Caren	Chief Commercial Officer	Sell	6,238	$6.73	$42.0K	13,762
Sep 20, 2021	GARDNER JASON	See Remarks	Sell	14,340	$6.73	$96.5K	286,872
Sep 20, 2021	Nichols David Wayne	Chief Technical Officer	Sell	5,694	$6.73	$38.3K	14,306
Sep 20, 2021	Stants Kristen	Chief People Officer	Sell	5,736	$6.73	$38.6K	14,264

DNTH Insider Buying Activity

The following table shows recent insider purchases of Dianthus Therapeutics, Inc. (DNTH) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Oct 3, 2023	Fairmount Funds Management LLC	Director	Buy	24,670	$13.63	$336.3K	1,928,503
Sep 28, 2023	Fairmount Funds Management LLC	Director	Buy	30,000	$13.15	$394.5K	1,903,833
Sep 25, 2023	Randhawa Simrat	Chief Medical Officer	Buy	4,000	$13.20	$52.8K	4,000
Sep 21, 2023	Fairmount Funds Management LLC	Director	Buy	30,000	$13.20	$396.0K	1,873,833
Sep 13, 2023	Fairmount Funds Management LLC		Buy	24,254	$11.20	$271.7K	1,843,833

DNTH Insider Selling Activity

The following table shows recent insider sales of Dianthus Therapeutics, Inc. (DNTH) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Mar 13, 2026	CARR EDWARD	officer: CHIEF ACCOUNTING OFFICER	Sell	43,682	$81.49	$3.56M	27,830
Mar 13, 2026	Garcia Marino	director, officer: CEO AND PRESIDENT	Sell	122,918	$81.49	$10.02M	79,413
Mar 13, 2026	Randhawa Simrat	officer: EVP, Head of R&D	Sell	33,830	$81.48	$2.76M	0
Dec 4, 2025	Savitz Ryan	CFO & CBO	Sell	20,000	$45.18	$903.6K	0
Nov 13, 2025	Randhawa Simrat	EVP, Head of R&D	Sell	196,538	$37.55	$7.38M	0
Sep 9, 2025	Savitz Ryan	CFO & CBO	Sell	20,000	$35.00	$700.0K	0
Feb 9, 2023	Third Rock Ventures IV, L.P.	10% Owner	Sell	3,700,000	$0.83	$3.06M	4,558,204
Sep 20, 2021	Beetham Thomas W.	See Remarks	Sell	6,103	$6.73	$41.1K	13,897
Sep 20, 2021	Deardorf Caren	Chief Commercial Officer	Sell	6,238	$6.73	$42.0K	13,762
Sep 20, 2021	GARDNER JASON	See Remarks	Sell	14,340	$6.73	$96.5K	286,872
Sep 20, 2021	Nichols David Wayne	Chief Technical Officer	Sell	5,694	$6.73	$38.3K	14,306
Sep 20, 2021	Stants Kristen	Chief People Officer	Sell	5,736	$6.73	$38.6K	14,264